GO:0034344 regulation of type III interferon production: Antiviral Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034344 describes any process that modulates the frequency, rate, or extent of type III interferon (IFN-lambda) production, the only known member of the type III interferon family.
• Type III interferon production is triggered by pattern recognition receptors such as RIG-I-like receptors (RLRs) that sense viral RNA and initiate MAVS-dependent signaling.
• Regulation occurs at multiple levels, including viral antagonism (e.g., influenza A NS1, PEDV NSP8) and host restriction factors such as ADAR1 that prevent endogenous RNA from triggering interferon responses.
• Dysregulation of type III interferon production is linked to viral pathogenesis, autoimmune conditions, and inflammatory skin diseases such as psoriasis.
• Key experimental approaches include CRISPR knockout, point mutation, knock-in, overexpression models, and CRISPR library screening to dissect the regulatory network.
• Understanding GO:0034344 provides a framework for therapeutic targeting of IFN-lambda in antiviral defense and immune-mediated diseases.
Description
Type III interferons, also known as interferon lambdas (IFN-lambda), constitute a distinct family of antiviral cytokines that signal through a heterodimeric receptor composed of IFNLR1 and IL10RB. The production of these cytokines is tightly controlled to avoid excessive inflammation and tissue damage. GO:0034344, regulation of type III interferon production, encompasses all molecular events that modulate the frequency, rate, or extent of IFN-lambda synthesis and secretion. This regulatory process is critical for host defense against viral infections and for maintaining immune homeostasis. Research into GO:0034344 has revealed that type III interferon production is initiated by cytosolic RNA sensors such as RIG-I and MDA5, which signal through the adaptor MAVS to activate IRF3 and NF-kB transcription factors. Viruses have evolved countermeasures to inhibit this pathway; for example, the influenza A virus NS1 protein antagonizes interferon induction, and porcine epidemic diarrhea virus NSP8 downregulates PEX13 to suppress MAVS-mediated IFN-III production. Host factors such as ADAR1 also play a role by preventing endogenous RNA from triggering interferon responses, thereby avoiding autoinflammation. Dysregulation of type III interferon production has been implicated in autoimmune kidney diseases, where type I interferon drives T cell cytotoxicity via IRF7 upregulation, and in psoriatic skin inflammation, where autophagy-based HMGB1 secretion by keratinocytes contributes to disease pathogenesis. These findings underscore the importance of understanding the regulatory mechanisms governing IFN-lambda production for developing targeted therapies.
regulation of type III interferon production At A Glance
| GO ID | GO:0034344 |
|---|---|
| GO term | regulation of type III interferon production |
| Ontology | biological_process |
| Synonym | regulation of type III IFN production |
| Major function | Modulates the frequency, rate, or extent of type III interferon (IFN-lambda) production |
| Definition source | QuickGO |
| Related processes | RIG-I-like receptor signaling, MAVS-dependent antiviral response, interferon regulatory factor activation |
| Key regulators | RIG-I, MDA5, MAVS, IRF3, IRF7, ADAR1, viral proteins NS1 and NSP8 |
What Is GO:0034344?
GO:0034344, regulation of type III interferon production, is a biological process defined as any process that modulates the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon family identified so far. This term encompasses positive and negative regulation at transcriptional, post-transcriptional, and secretory levels, integrating signals from pattern recognition receptors, viral antagonists, and host restriction factors.
Why Is regulation of type III interferon production Important in Cell Biology?
Regulation of type III interferon production is essential for antiviral immunity and immune homeostasis. Type III interferons act primarily at epithelial barriers, where they induce antiviral effector programs without causing systemic inflammation. Dysregulation can lead to increased susceptibility to viral infections, autoimmune pathology, and chronic inflammatory diseases. Understanding GO:0034344 provides insights into host-pathogen interactions and offers potential targets for therapeutic intervention in infectious and immune-mediated diseases.
• Controls antiviral defense at mucosal surfaces, particularly in the respiratory and gastrointestinal tracts.
• Prevents excessive inflammation by restricting interferon responses to epithelial tissues.
• Viral pathogens such as influenza A and PEDV target this pathway to evade host immunity.
• Host factors like ADAR1 regulate endogenous RNA to avoid autoinflammatory interferon production.
• Dysregulation is associated with autoimmune kidney diseases and psoriatic skin inflammation.
• Provides a basis for developing broad-spectrum antivirals and immune modulators.
• Enables research into cell-type-specific interferon responses using CRISPR models.
• Supports biomarker discovery for viral susceptibility and autoimmune conditions.
What Happens During regulation of type III interferon production?
Viral RNA sensing by RIG-I-like receptors
In simple terms: When a virus enters a cell, specialized sensor proteins detect its genetic material and start an alarm.
RIG-I-like receptors (RLRs), including RIG-I and MDA5, recognize cytosolic viral RNA and undergo conformational changes that expose their caspase activation and recruitment domains (CARDs). These domains interact with the mitochondrial antiviral signaling protein (MAVS) to initiate a signaling cascade. This step is a primary trigger for type III interferon production.
MAVS-dependent signaling and transcription factor activation
In simple terms: The alarm signal travels through a chain of proteins to the nucleus, where it turns on interferon genes.
MAVS forms prion-like aggregates on mitochondria and peroxisomes, recruiting downstream kinases TBK1 and IKK-epsilon. These kinases phosphorylate IRF3 and IRF7, which then translocate to the nucleus and bind to promoter regions of type III interferon genes, driving their transcription. NF-kB is also activated to synergize with IRFs.
Viral antagonism of IFN-III production
In simple terms: Viruses fight back by making proteins that block the alarm system.
Influenza A virus NS1 protein inhibits RIG-I-mediated signaling and interferon induction. Porcine epidemic diarrhea virus NSP8 downregulates PEX13, a peroxisomal protein, to suppress MAVS-dependent IFN-III production. These viral countermeasures highlight the evolutionary arms race between host and pathogen.
Host restriction by ADAR1
In simple terms: A host enzyme edits RNA to prevent the cell from mistaking its own RNA for a virus.
ADAR1 (adenosine deaminase acting on RNA) converts adenosine to inosine in endogenous double-stranded RNA, preventing activation of MDA5 and subsequent interferon production. Loss of ADAR1 leads to translational shutdown and autoinflammatory interferon responses. This regulatory mechanism is critical for avoiding autoimmunity.
Feedback and fine-tuning by interferons
In simple terms: Interferons can amplify or dampen their own production to keep the response balanced.
Type I interferons can upregulate IRF7, creating a positive feedback loop that enhances interferon production. Conversely, excessive interferon signaling can induce negative regulators such as SOCS proteins and USP18. The balance between positive and negative feedback determines the magnitude and duration of type III interferon production.
Key Genes Involved in GO:0034344 regulation of type III interferon production
The following genes and proteins are central to the regulation of type III interferon production, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RIG-I (DDX58) | Cytosolic sensor of short double-stranded RNA; initiates MAVS signaling | Knockout reduces IFN-III production; target for antiviral research |
| MDA5 (IFIH1) | Senses long double-stranded RNA; activates MAVS | Mutations linked to autoimmune diseases; KO models available |
| MAVS | Mitochondrial adaptor protein; essential for RLR signaling | Central node; KO abolishes IFN-III induction |
| IRF3 | Transcription factor; activates IFN-III gene promoters | Phosphorylation status determines activity; point mutants useful |
| IRF7 | Transcription factor; amplifies interferon production | Upregulated by type I IFN; KO reduces IFN-III |
| ADAR1 (ADAR) | RNA editing enzyme; prevents endogenous RNA sensing | KO causes autoinflammation; editing-deficient mutants available |
| NS1 (influenza A) | Viral protein; antagonizes RIG-I signaling | Viral evasion factor; target for attenuated vaccines |
| NSP8 (PEDV) | Viral protein; downregulates PEX13 to inhibit MAVS | Viral antagonist; useful for studying peroxisomal regulation |
| PEX13 | Peroxisomal protein; facilitates MAVS signaling | Knockdown reduces IFN-III; links peroxisomes to immunity |
| TBK1 | Kinase; phosphorylates IRF3/IRF7 | Essential for IFN induction; KO lethal |
| IKK-epsilon (IKBKE) | Kinase; activates IRF3/IRF7 | Redundant with TBK1; KO models available |
| HMGB1 | Alarmin; secreted by keratinocytes in psoriasis | Links inflammation to IFN production; KO reduces skin inflammation |
| IFNLR1 | Type III interferon receptor subunit | KO abolishes IFN-lambda signaling |
| IL10RB | Shared receptor subunit for IFN-lambda | Mutations cause immunodeficiency |
| STAT1 | Transcription factor downstream of IFN receptor | KO abolishes IFN-stimulated gene induction |
| STAT2 | Transcription factor downstream of IFN receptor | KO impairs antiviral responses |
| IRF9 | Forms ISGF3 complex with STAT1/STAT2 | KO reduces IFN-stimulated gene expression |
How Is regulation of type III interferon production Regulated?
Regulation of type III interferon production is controlled by multiple layers of feedback and crosstalk. Type I interferons can prime cells by upregulating IRF7, enhancing subsequent IFN-III production. Conversely, sustained interferon signaling induces negative regulators such as SOCS1 and USP18, which dampen the response. Viral proteins like NS1 and NSP8 directly inhibit signaling intermediates. Host RNA editing by ADAR1 prevents aberrant activation by endogenous RNA. Additionally, autophagy-mediated secretion of HMGB1 in keratinocytes contributes to psoriatic inflammation, indirectly influencing interferon production. These regulatory mechanisms ensure a balanced antiviral response while preventing autoimmunity.
regulation of type III interferon production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADAR1 | Aicardi-Goutieres syndrome; autoinflammation | Knockout or editing-deficient knock-in mice |
| IRF7 | Autoimmune kidney diseases; T cell cytotoxicity | Conditional knockout in T cells |
| HMGB1 | Psoriasis; skin inflammation | Keratinocyte-specific knockout |
| MAVS | Viral susceptibility; impaired IFN-III production | Knockout cell lines and mice |
| NS1 (influenza A) | Viral immune evasion; enhanced pathogenesis | Recombinant viruses with NS1 mutations |
Viral infections and immune evasion
Many viruses target the regulation of type III interferon production to evade host immunity. Influenza A virus NS1 protein inhibits RIG-I-mediated signaling, reducing IFN-lambda production and enhancing viral replication. Porcine epidemic diarrhea virus NSP8 downregulates PEX13 to suppress MAVS-dependent IFN-III production, facilitating viral spread. These examples illustrate how viral antagonism of GO:0034344 contributes to pathogenesis.
Autoimmune and inflammatory diseases
Dysregulated interferon production is a hallmark of autoimmune diseases such as systemic lupus erythematosus and psoriasis. In autoimmune kidney diseases, type I interferon drives T cell cytotoxicity via IRF7 upregulation, and similar mechanisms may affect type III interferon. In psoriasis, autophagy-based HMGB1 secretion by keratinocytes promotes inflammation, which may involve interferon pathways. ADAR1 mutations cause Aicardi-Goutieres syndrome, an autoinflammatory disorder characterized by excessive interferon production.
Cancer and immunotherapy
Type III interferons have been implicated in antitumor immunity, particularly at mucosal surfaces. Regulation of IFN-lambda production can influence tumor immune surveillance. However, direct evidence linking GO:0034344 to cancer remains limited, and further research is needed to establish causal relationships.
From regulation of type III interferon production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate IFN-III production? | CRISPR knockout in epithelial cell lines (e.g., A549, HT-29) |
| What is the role of a specific phosphorylation site? | Point mutation knock-in (e.g., IRF3 S396A) |
| How does a viral protein antagonize IFN-III? | Overexpression of viral protein in reporter cell lines |
| What is the spatiotemporal dynamics of IFN-III production? | Tagged knock-in (e.g., IFN-lambda-GFP) in primary cells |
| Which genes are essential for IFN-III induction? | Genome-wide CRISPR library screening |
| Does a disease-associated SNP affect IFN-III regulation? | Knock-in of SNP using CRISPR in patient-derived iPSCs |
How to Study the regulation of type III interferon production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter assay | IFN-lambda promoter activity | Screening for regulators and viral antagonists |
| RNA-seq | Global transcriptome changes | Identifying interferon-stimulated genes and feedback loops |
| CRISPR knockout screening | Essential genes for IFN-III production | Unbiased discovery of pathway components |
| Co-immunoprecipitation | Protein-protein interactions | Mapping viral-host protein complexes |
| Western blot | Protein expression and phosphorylation | Validating signaling activation (e.g., IRF3 phosphorylation) |
| ELISA | Secreted IFN-lambda protein levels | Quantifying production in cell culture supernatants |
| Flow cytometry | Single-cell IFN-lambda expression | Analyzing heterogeneity in responding cells |
| Proximity ligation assay | In situ protein interactions | Visualizing MAVS signaling complexes |
Reporter-based assays for IFN-III production
Luciferase or fluorescent reporters driven by the IFN-lambda promoter can be used to measure transcriptional activity in live cells. These assays are suitable for high-throughput screening of regulators and viral antagonists.
RNA sequencing and transcriptomics
RNA-seq allows global profiling of gene expression changes upon modulation of candidate regulators. It can identify interferon-stimulated genes and feedback regulators, providing a systems-level view of GO:0034344.
CRISPR screening for regulators
Genome-wide CRISPR knockout or activation screens coupled with IFN-lambda reporter readouts can identify novel positive and negative regulators. This unbiased approach has been instrumental in mapping signaling pathways.
Protein-protein interaction studies
Co-immunoprecipitation, proximity ligation, and mass spectrometry can reveal interactions between viral proteins and host signaling components, such as NS1 with RIG-I or NSP8 with PEX13.
How CRISPR Can Be Used to Study GO:0034344 regulation of type III interferon production
Knockout
CRISPR knockout of candidate genes such as MAVS, IRF3, or ADAR1 can definitively test their requirement for type III interferon production. Knockout cell lines and mice are valuable for dissecting signaling pathways and disease models.
Point Mutation
Introducing precise point mutations (e.g., in IRF3 phosphorylation sites or ADAR1 catalytic residues) allows researchers to study the impact of specific modifications on IFN-III regulation without altering protein levels.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) into the IFN-lambda locus enables real-time monitoring of production in live cells and tissues. Knock-in of disease-associated SNPs can model genetic susceptibility.
Overexpression
Overexpression of viral antagonists (e.g., NS1, NSP8) or host regulators (e.g., IRF7) can reveal their sufficiency to modulate IFN-III production and identify dominant-negative effects.
How EDITGENE Supports regulation of type III interferon production Research
Researchers studying regulation of type III interferon production-related genes often need to determine whether a candidate gene is causally involved in the pathway, and CRISPR-based models provide the most direct approach. EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for regulation of type III interferon production research.
Frequently Asked Questions About regulation of type III interferon production
What is GO:0034344?
GO:0034344 is a Gene Ontology term for regulation of type III interferon production, defined as any process that modulates the frequency, rate, or extent of type III interferon (IFN-lambda) production.
What genes are involved in regulation of type III interferon production?
Key genes include RIG-I (DDX58), MDA5 (IFIH1), MAVS, IRF3, IRF7, ADAR1, and viral genes such as influenza NS1 and PEDV NSP8.
How is type III interferon production regulated?
It is regulated by pattern recognition receptors, MAVS-dependent signaling, transcription factors IRF3/IRF7, host RNA editing by ADAR1, and viral antagonists.
What is the difference between type I and type III interferon?
Type I interferons (e.g., IFN-alpha/beta) signal through IFNAR, while type III interferons (IFN-lambda) signal through IFNLR1/IL10RB and act primarily at epithelial barriers.
Which viruses inhibit type III interferon production?
Influenza A virus NS1 and porcine epidemic diarrhea virus NSP8 are known to inhibit IFN-III production.
What diseases are associated with dysregulated type III interferon production?
Autoimmune kidney diseases, psoriasis, and Aicardi-Goutieres syndrome have been linked to dysregulated interferon production.
How can I study regulation of type III interferon production?
Use CRISPR knockout, point mutation, knock-in reporters, overexpression, and CRISPR screening in combination with RNA-seq and reporter assays.
What cell models are suitable for IFN-III research?
Epithelial cell lines such as A549 and HT-29, as well as primary keratinocytes and immune cells, are commonly used.
Does ADAR1 regulate type III interferon production?
ADAR1 prevents endogenous RNA from triggering interferon responses; loss of ADAR1 leads to autoinflammatory interferon production.
What is the role of MAVS in type III interferon production?
MAVS is a central adaptor protein that links RIG-I/MDA5 sensing to downstream IRF3/IRF7 activation and IFN-III transcription.
Conclusion
GO:0034344, regulation of type III interferon production, is a critical biological process that governs antiviral immunity at mucosal surfaces. Its dysregulation contributes to viral pathogenesis and autoimmune diseases. Continued research using CRISPR-based models will uncover new regulatory mechanisms and therapeutic targets. EDITGENE provides comprehensive services to support these investigations.
References
- 1. Onomoto K et al.. 2021. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors.. Cell Mol Immunol 18(3):539-555 PMID: 33462384
- 2. Zhang X et al.. 2024. Research progress on the nonstructural protein 1 (NS1) of influenza a virus.. Virulence 15(1):2359470 PMID: 38918890
- 4. Wang Z et al.. 2021. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation.. Autophagy 17(2):529-552 PMID: 32019420
- 5. Wang H et al.. 2025. Type I interferon drives T cell cytotoxicity by upregulation of interferon regulatory factor 7 in autoimmune kidney diseases in mice.. Nat Commun 16(1):4686 PMID: 40393992
- 6. Chung H et al.. 2018. Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown.. Cell 172(4):811-824.e14 PMID: 29395325
- 7. Lou J et al.. 2025. PEDV NSP8 inhibits IFN-III production induced by MAVS through downregulation of PEX13.. mBio 16(12):e0239625 PMID: 41186416
